Stockscreener 앱 받기
30.17
2.11%
-0.65
시간 외 거래:
30.17
Atricure Inc 주식(ATRC)의 최신 뉴스
What drives AtriCure Inc. stock priceRapid profit acceleration - jammulinksnews.com
What analysts say about AtriCure Inc. stockExceptional profit margins - jammulinksnews.com
Is AtriCure Inc. a good long term investmentDynamic investment opportunities - jammulinksnews.com
AtriCure Inc. Stock Analysis and ForecastRapid wealth accumulation - Autocar Professional
Left Atrial Appendage Closure (LAAC) Device Market Key Players, Share and Forecast Outlook - openPR.com
AtriCure Shares Plunge 1.65% Amid FDA Approval Concerns - AInvest
AtriCure Inc. (ATRC) shares plunge 2.07% to lowest since May 2025 - AInvest
AtriCure Inc. (ATRC) Drops 2.94% in Two Days, Hits 2025 Low - AInvest
AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention - BioSpace
Why AtriCure Inc. stock attracts strong analyst attentionMarket Timing Advice - Newser
Why RadNet Inc. stock attracts strong analyst attentionReal Time Alert Service - Newser
How AtriCure Inc. stock performs during market volatilityFree Predictions - Newser
AtriCure completes enrollment in landmark cardiac stroke prevention trial By Investing.com - Investing.com Canada
AtriCure completes enrollment in landmark cardiac stroke prevention trial - Investing.com Australia
What makes AtriCure Inc. stock price move sharplyRisk Adjusted Stock Signals - Newser
AtriCure, Inc. (ATRC) Stock Analysis: Unveiling a 59% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Left Atrial Appendage Closure Devices Market Exclusive Report - openPR.com
(ATRC) On The My Stocks Page - news.stocktradersdaily.com
AtriCure Data Breach Investigation - Claim Depot
Artivion Inc. Data Breach Affects 5,608 in Texas: SSNs Exposed - Claim Depot
AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry? - simplywall.st
AtriCure to Announce Second Quarter 2025 Financial Results - The Globe and Mail
AtriCure, Inc. (NASDAQ:ATRC) Receives Consensus Rating of “Buy” from Analysts - Defense World
AtriCure, Inc.(NasdaqGM: ATRC) dropped from Russell 3000E Value Index - MarketScreener
AtriCure (ATRC): Leveraging Regulatory Wins and Insider Backing in a Declining Market - AInvest
AtriCure: Profits And Operating Leverage Are Needed Here (NASDAQ:ATRC) - Seeking Alpha
Cryoablation Probe Market Size, Share | Industry Report 2030 - Grand View Research
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year? - Yahoo Finance
Transcript : AtriCure, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener
AtriCure at Goldman Sachs Conference: Strategic Growth Insights - Investing.com India
AtriCure at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com UK
AtriCure's Strategic Momentum: Leadership in Atrial Fibrillation Management Takes Center Stage - AInvest
Ameriprise Financial Inc. Invests $295,000 in AtriCure, Inc. (NASDAQ:ATRC) - Defense World
Global Cardiac Ablation Market: Advancements in Minimally Invasive Procedures and 13% CAGR by 2030 - PharmiWeb.com
Left Atrial Appendage Closure Device Market projected to surpass US$ 8,786.032 million by 2030 at a CAGR of - EIN News
AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Jane Street Group LLC - Defense World
AtriCure (NASDAQ:ATRC) Downgraded to “Hold” Rating by Wall Street Zen - Defense World
(ATRC) Investment Analysis - news.stocktradersdaily.com
AtriCure’s chief scientific officer sells $83,600 in stock By Investing.com - Investing.com India
Insider Sell: Vinayak Doraiswamy Sells 2,500 Shares of AtriCure Inc (ATRC) - GuruFocus
AtriCure’s chief scientific officer sells $83,600 in stock - Investing.com Australia
0.63%
0.57%
자본화:
|
볼륨(24시간):